dihydroxyphenylalanine has been researched along with MPTP Neurotoxicity Syndrome in 19 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We retrospectively analyzed data from 17 stable HP rhesus monkeys treated long-term with chronic intermittent dosing of levodopa (LD) in an attempt to induce choreoathetoid and dystonic dyskinesias." | 1.37 | Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys. ( Bakay, RA; Deogaonkar, M; Lieu, CA; Subramanian, T, 2011) |
| " Overall, these results suggest that, at least in 1-year-old mice, dietary restriction for 3 months does not protect nigral DA nerve terminals from low toxic dosages of MPTP." | 1.32 | Dietary restriction does not protect the nigrostriatal dopaminergic pathway of older animals from low-dose MPTP-induced neurotoxicity. ( Morgan, WW; Nelson, JF; Richardson, AG, 2003) |
| " Solutions of TOPA were also toxic to mesencephalic neurons after acute or chronic exposure, displaying the same leftward shift in LD50." | 1.28 | Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease. ( Dal Toso, R; Facci, L; Leon, A; Moroni, F; Schiavo, N; Skaper, SD; Vantini, G, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 7 (36.84) | 18.2507 |
| 2000's | 6 (31.58) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pavshintsev, VV | 1 |
| Podshivalova, LS | 1 |
| Frolova, OY | 1 |
| Belopolskaya, MV | 1 |
| Averina, OA | 1 |
| Kushnir, EA | 1 |
| Marmiy, NV | 1 |
| Lovat, ML | 1 |
| Kanazawa, M | 1 |
| Ohba, H | 1 |
| Harada, N | 1 |
| Kakiuchi, T | 1 |
| Muramatsu, S | 1 |
| Tsukada, H | 2 |
| Xu, Q | 1 |
| Jiang, X | 1 |
| Ke, Y | 1 |
| Zhang, S | 1 |
| Xu, R | 1 |
| Zeng, Y | 1 |
| Lieu, CA | 1 |
| Deogaonkar, M | 1 |
| Bakay, RA | 1 |
| Subramanian, T | 1 |
| Asakawa, T | 1 |
| Sugiyama, K | 1 |
| Akamine, S | 1 |
| Yokoyama, C | 1 |
| Shukuri, M | 1 |
| Mizuma, H | 1 |
| Onoe, H | 1 |
| Namba, H | 1 |
| Dall, AM | 1 |
| Danielsen, EH | 1 |
| Sørensen, JC | 1 |
| Andersen, F | 1 |
| Møller, A | 1 |
| Zimmer, J | 1 |
| Gjedde, AH | 1 |
| Cumming, P | 1 |
| Morgan, WW | 1 |
| Richardson, AG | 1 |
| Nelson, JF | 1 |
| Andringa, G | 1 |
| Eshuis, S | 1 |
| Perentes, E | 1 |
| Maguire, RP | 1 |
| Roth, D | 1 |
| Ibrahim, M | 1 |
| Leenders, KL | 1 |
| Cools, AR | 1 |
| Nagai, Y | 1 |
| Obayashi, S | 1 |
| Ando, K | 1 |
| Inaji, M | 1 |
| Maeda, J | 1 |
| Okauchi, T | 1 |
| Ito, H | 1 |
| Suhara, T | 1 |
| Gold, SJ | 1 |
| Hoang, CV | 1 |
| Potts, BW | 1 |
| Porras, G | 1 |
| Pioli, E | 1 |
| Kim, KW | 1 |
| Nadjar, A | 1 |
| Qin, C | 1 |
| LaHoste, GJ | 1 |
| Li, Q | 1 |
| Bioulac, BH | 1 |
| Waugh, JL | 1 |
| Gurevich, E | 1 |
| Neve, RL | 1 |
| Bezard, E | 1 |
| Richard, MG | 1 |
| Bennett, JP | 1 |
| Pate, BD | 1 |
| Kawamata, T | 1 |
| Yamada, T | 1 |
| McGeer, EG | 1 |
| Hewitt, KA | 1 |
| Snow, BJ | 1 |
| Ruth, TJ | 1 |
| Calne, DB | 1 |
| Popkova, EV | 1 |
| Krupina, NA | 1 |
| Kryzhanovskiĭ, GN | 1 |
| Orlova, IN | 1 |
| Iordanskaia, TE | 1 |
| Fernández-Ruiz, J | 1 |
| Doudet, D | 1 |
| Aigner, TG | 4 |
| Hirata, Y | 1 |
| Kiuchi, K | 1 |
| Nagatsu, T | 1 |
| Skaper, SD | 1 |
| Facci, L | 1 |
| Schiavo, N | 1 |
| Vantini, G | 1 |
| Moroni, F | 1 |
| Dal Toso, R | 1 |
| Leon, A | 1 |
| Doudet, DJ | 3 |
| McLellan, CA | 3 |
| Wyatt, RJ | 1 |
| Cohen, RM | 3 |
| Brücke, T | 1 |
| Miyake, H | 1 |
| Finn, RT | 1 |
| Wan, RQ | 1 |
| Adams, HR | 1 |
19 other studies available for dihydroxyphenylalanine and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Effects of Mitochondrial Antioxidant SkQ1 on Biochemical and Behavioral Parameters in a Parkinsonism Model in Mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antioxidants; Brain; Dihydroxyphenylalanine; Dopamine; Immu | 2017 |
Evaluation of 6-11C-Methyl-m-Tyrosine as a PET Probe for Presynaptic Dopaminergic Activity: A Comparison PET Study with β-11C-l-DOPA and 18F-FDOPA in Parkinson Disease Monkeys.
Topics: Animals; Brain; Carbidopa; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport Proteins; Dopa | 2016 |
Gene therapy in hemiparkinsonian rhesus monkeys: long-term survival and behavioral recovery by transplantation of autologous human tyrosine hydroxylase-expressing neural stem cells.
Topics: Animals; Behavior, Animal; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Dihydroxyphe | 2010 |
Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Carot | 2011 |
The food reaching test: a sensitive test of behavioral improvements by deep brain stimulation in MPTP-treated monkey.
Topics: Animals; Carbon Radioisotopes; Cocaine; Corpus Striatum; Deep Brain Stimulation; Dihydroxyphenylalan | 2012 |
Quantitative [18F]fluorodopa/PET and histology of fetal mesencephalic dopaminergic grafts to the striatum of MPTP-poisoned minipigs.
Topics: Animals; Behavior, Animal; Brain Tissue Transplantation; Cell Line; Corpus Striatum; Dihydroxyphenyl | 2002 |
Dietary restriction does not protect the nigrostriatal dopaminergic pathway of older animals from low-dose MPTP-induced neurotoxicity.
Topics: Animals; Corpus Striatum; Diet, Reducing; Dihydroxyphenylalanine; Dopamine; Male; Mice; Mice, Inbred | 2003 |
TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Macaca mulatta; Male; Motor Skills Disorders; MPTP | 2003 |
Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain; Dihydroxyphenylalanine; Disease Models, Anim | 2007 |
RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Corpus Striatum; Dihydroxyphenylalanine; Disease Mo | 2007 |
Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Corpus Striatum; Dihydroxyphenylalanine; Dopa | 1994 |
Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices.
Topics: Animals; Biological Transport; Dihydroxyphenylalanine; Dopamine; Fluorine Radioisotopes; Macaca fasc | 1993 |
[Monoamine level in the rat brain with MPTP-induced depressive syndrome].
Topics: Animals; Biogenic Monoamines; Brain; Depressive Disorder; Dihydroxyphenylalanine; Dopamine; Dopamine | 1999 |
Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys.
Topics: Animals; Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine Agents; Fluorine Radioisotopes; Levo | 1999 |
Manganese mimics the action of 1-methyl-4-phenylpyridinium ion, a dopaminergic neurotoxin, in rat striatal tissue slices.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dihydroxyphenylalanine; Dopamine; Dose-Respon | 2001 |
Characterization of 2,4,5-trihydroxyphenylalanine neurotoxicity in vitro and protective effects of ganglioside GM1: implications for Parkinson's disease.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Cells, Cultured; Cerebellum; Dihydroxyphenylalanine; | 1992 |
Delayed L-phenylalanine infusion allows for simultaneous kinetic analysis and improved evaluation of specific-to-nonspecific fluorine-18-dopa uptake in brain.
Topics: Animals; Brain; Carbidopa; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Macaca mulatta; | 1992 |
New rapid analysis method demonstrates differences in 6-[18F] fluoro-L-dopa plasma input curves with and without carbidopa and in hemi-MPTP lesioned monkeys.
Topics: Animals; Carbidopa; Dihydroxyphenylalanine; Dopamine; Fluorine Radioisotopes; Functional Laterality; | 1991 |
6-18F-L-dopa imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Female; Macaca; Macaca | 1989 |